Daiwa Securities Group Inc. Acquires 350 Shares of ICU Medical, Inc. (NASDAQ:ICUI)

Daiwa Securities Group Inc. raised its position in ICU Medical, Inc. (NASDAQ:ICUI) by 1.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,612 shares of the medical instruments supplier’s stock after buying an additional 350 shares during the period. Daiwa Securities Group Inc. owned 0.12% of ICU Medical worth $2,854,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ICUI. Wellington Management Group LLP boosted its position in ICU Medical by 71.6% in the first quarter. Wellington Management Group LLP now owns 1,516,089 shares of the medical instruments supplier’s stock valued at $337,542,000 after buying an additional 632,609 shares in the last quarter. FMR LLC lifted its holdings in ICU Medical by 89.9% in the third quarter. FMR LLC now owns 1,124,995 shares of the medical instruments supplier’s stock valued at $133,886,000 after buying an additional 532,483 shares during the period. Morgan Stanley lifted its holdings in ICU Medical by 233.5% in the fourth quarter. Morgan Stanley now owns 679,912 shares of the medical instruments supplier’s stock valued at $107,073,000 after buying an additional 476,012 shares during the period. Fuller & Thaler Asset Management Inc. lifted its holdings in ICU Medical by 59.2% in the third quarter. Fuller & Thaler Asset Management Inc. now owns 1,015,006 shares of the medical instruments supplier’s stock valued at $120,796,000 after buying an additional 377,532 shares during the period. Finally, Vanguard Group Inc. increased its stake in ICU Medical by 8.8% in the first quarter. Vanguard Group Inc. now owns 2,122,104 shares of the medical instruments supplier’s stock valued at $472,466,000 after purchasing an additional 171,851 shares in the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at ICU Medical

In other news, VP Daniel Woolson sold 791 shares of the stock in a transaction on Friday, March 15th. The shares were sold at an average price of $98.27, for a total transaction of $77,731.57. Following the completion of the sale, the vice president now owns 13,980 shares of the company’s stock, valued at $1,373,814.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, VP Daniel Woolson sold 791 shares of the stock in a transaction on Friday, March 15th. The shares were sold at an average price of $98.27, for a total transaction of $77,731.57. Following the completion of the sale, the vice president now owns 13,980 shares of the company’s stock, valued at $1,373,814.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Christian B. Voigtlander sold 13,603 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $107.19, for a total transaction of $1,458,105.57. The disclosure for this sale can be found here. Insiders sold 24,262 shares of company stock valued at $2,545,532 over the last quarter. Corporate insiders own 6.70% of the company’s stock.

Wall Street Analyst Weigh In

Separately, KeyCorp upped their target price on shares of ICU Medical from $134.00 to $136.00 and gave the company an “overweight” rating in a research note on Wednesday, February 28th. One research analyst has rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $123.00.

ICU Medical Stock Down 1.2 %

Shares of NASDAQ:ICUI opened at $95.77 on Monday. ICU Medical, Inc. has a 52 week low of $78.28 and a 52 week high of $212.43. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.06 and a current ratio of 2.53. The company has a market capitalization of $2.33 billion, a PE ratio of -77.86 and a beta of 0.69. The company has a 50 day moving average price of $102.30 and a two-hundred day moving average price of $98.34.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Tuesday, February 27th. The medical instruments supplier reported $1.24 EPS for the quarter, beating the consensus estimate of $0.85 by $0.39. ICU Medical had a negative net margin of 1.31% and a positive return on equity of 6.35%. The firm had revenue of $587.86 million during the quarter, compared to the consensus estimate of $564.77 million. Analysts forecast that ICU Medical, Inc. will post 3.52 earnings per share for the current year.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.